Needham analyst Ryan Macdonald initiated coverage on Hims & Hers Health Inc. (NYSE:HIMS) at a Buy rating with a price target of $24.
The analyst writes that, despite increased stock volatility with its entry into the compounded GLP-1 market, he anticipates a positive impact on HIMS’s fundamentals and sees strong growth potential.
With the weight loss market valued at around $373 billion, HIMS is well-positioned to capitalize on this opportunity, addressing key barriers of cost and access to treatment, adds the analyst.
Macdonald says that HIMS is not solely dependent on GLP-1; the company is already growing at over 40% with revenues exceeding $1 billion, and it has multiple growth drivers and margin expansion opportunities through higher acuity care and personalized, margin-accretive products.
The analyst expects EBITDA of $147.6 million in FY24 and $233.1 million in FY25.
This month, the company reported quarterly earnings of six cents per share, which beat the analyst consensus estimate of three cents. Sales of $315.648 million beat the analyst consensus estimate by 5.24%.
Hims & Hers expects third-quarter revenue in a range of $375 million-$380 million and full-year revenue of $1.37 billion-$1.4 billion.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify Online Retail ETF (NYSE:IBUY) and Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH).
HIMS Price Action: Hims & Hers Health shares are down 0.12% at $16.55 at publication Thursday.
Read Next:
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Courtesy of Hims & Hers Health, Inc.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
